"The successful trial is run by the company that picks up Brilacidin for nothing just as did IP before."
That assumes that this hypothetical acquirer runs the company as a real company rather than as a vehicle to enrich the crooked insiders, which is how it's currently operated.
best case? B succeeds in the trial and works for other viruses as well. Nonetheless: Critical time lost as competition for treatment heats up and hospitals have been full of those needing treatment for many months already. B would already be standard of treatment had this been done 3 months ago.
You know, when everyone here said it would happen....